Alkem Laboratories Reports Q3 Profit Of ₹6.36 Billion, Announces Occutech Acquisition

Alkem Laboratories Ltd, one of India’s leading pharmaceutical companies, has released its December quarter results, posting a consolidated net profit of ₹6.36 billion. This figure came in marginally below IBES estimates of ₹6.51 billion. Revenue from operations stood at ₹37.37 billion, compared to market expectations of ₹37.6 billion, reflecting steady demand across therapeutic segments.  

Alongside its financial results, Alkem announced a strategic acquisition through its subsidiary Alkem Medtech, which will purchase a 51%–55% stake in Occutech. The total equity value of the deal is estimated at EUR 180.70 million, underscoring Alkem’s commitment to expanding its footprint in medical technology and strengthening its diversified portfolio.  

Analysts note that while quarterly earnings were slightly below estimates, the acquisition signals Alkem’s focus on long-term growth and innovation. The move is expected to enhance its presence in specialized healthcare solutions, complementing its strong pharmaceutical base.  

Key highlights from the announcement include  

• Consolidated net profit of ₹6.36 billion in Q3 FY26  
• Revenue from operations reported at ₹37.37 billion  
• Earnings slightly below IBES estimates of ₹6.51 billion profit and ₹37.6 billion revenue  
• Alkem Medtech to acquire 51%–55% stake in Occutech  
• Total equity value of the acquisition estimated at EUR 180.70 million  
• Company reinforces focus on diversification and medical technology expansion  

Industry experts emphasize that Alkem’s financial performance, combined with its strategic acquisition, positions the company for sustained growth in both pharmaceuticals and medtech sectors.  

Sources: Reuters, Economic Times, Business Standard